Terms: = Ovarian cancer AND PDGFRB, JTK12, 5159, P09619, ENSG00000113721, PDGF-R-beta, PDGFR1, CD140B, PDGFR, CD140b
80 results:
1. Suppressive stroma-immune prognostic signature impedes immunotherapy in ovarian cancer and can be reversed by pdgfrb inhibitors.
Yang D; Duan MH; Yuan QE; Li ZL; Luo CH; Cui LY; Li LC; Xiao Y; Zhu XY; Zhang HL; Feng GK; Liu GC; Deng R; Li JD; Zhu XF
J Transl Med; 2023 Sep; 21(1):586. PubMed ID: 37658364
[TBL] [Abstract] [Full Text] [Related]
2. An angiogenic tumor phenotype predicts poor prognosis in ovarian cancer.
Wieser V; Tsibulak I; Reimer DU; Zeimet AG; Fiegl H; Hackl H; Marth C
Gynecol Oncol; 2023 Mar; 170():290-299. PubMed ID: 36758419
[TBL] [Abstract] [Full Text] [Related]
3. TMEM119 facilitates ovarian cancer cell proliferation, invasion, and migration via the pdgfrb/PI3K/AKT signaling pathway.
Sun T; Bi F; Liu Z; Yang Q
J Transl Med; 2021 Mar; 19(1):111. PubMed ID: 33731124
[TBL] [Abstract] [Full Text] [Related]
4. Phase II trial of bevacizumab and sorafenib in recurrent ovarian cancer patients with or without prior-bevacizumab treatment.
Lee JM; Annunziata CM; Hays JL; Cao L; Choyke P; Yu M; An D; Turkbey IB; Minasian LM; Steinberg SM; Chen H; Wright J; Kohn EC
Gynecol Oncol; 2020 Oct; 159(1):88-94. PubMed ID: 32747013
[TBL] [Abstract] [Full Text] [Related]
5. A randomized phase II evaluation of weekly gemcitabine plus pazopanib versus weekly gemcitabine alone in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma.
Duska LR; Petroni GR; Varhegyi N; Brown J; Jelovac D; Moore KN; McGuire WP; Darus C; Barroilhet LM; Secord AA
Gynecol Oncol; 2020 Jun; 157(3):585-592. PubMed ID: 32247603
[TBL] [Abstract] [Full Text] [Related]
6. Uterine mesenchymal tumours: recent advances.
Momeni-Boroujeni A; Chiang S
Histopathology; 2020 Jan; 76(1):64-75. PubMed ID: 31846533
[TBL] [Abstract] [Full Text] [Related]
7. Anti-angiogenic effects of crenolanib are mediated by mitotic modulation independently of pdgfr expression.
Berndsen RH; Castrogiovanni C; Weiss A; Rausch M; Dallinga MG; Miljkovic-Licina M; Klaassen I; Meraldi P; van Beijnum JR; Nowak-Sliwinska P
Br J Cancer; 2019 Jul; 121(2):139-149. PubMed ID: 31235865
[TBL] [Abstract] [Full Text] [Related]
8. Cediranib suppresses homology-directed DNA repair through down-regulation of BRCA1/2 and RAD51.
Kaplan AR; Gueble SE; Liu Y; Oeck S; Kim H; Yun Z; Glazer PM
Sci Transl Med; 2019 May; 11(492):. PubMed ID: 31092693
[TBL] [Abstract] [Full Text] [Related]
9. Gene expression differences between matched pairs of ovarian cancer patient tumors and patient-derived xenografts.
Liu Y; Chanana P; Davila JI; Hou X; Zanfagnin V; McGehee CD; Goode EL; Polley EC; Haluska P; Weroha SJ; Wang C
Sci Rep; 2019 Apr; 9(1):6314. PubMed ID: 31004097
[TBL] [Abstract] [Full Text] [Related]
10. The expression of Platelet-derived Growth factor receptors (pdgfrs) and their correlation with overall survival of patients with ovarian cancer.
Szubert S; Moszynski R; Szpurek D; Romaniuk B; Sajdak S; Nowicki M; Michalak S
Ginekol Pol; 2019; 90(5):242-249. PubMed ID: 30977516
[TBL] [Abstract] [Full Text] [Related]
11. Molecular Characterization of Non-responders to Chemotherapy in Serous ovarian cancer.
McDonald ME; Salinas EA; Devor EJ; Newtson AM; Thiel KW; Goodheart MJ; Bender DP; Smith BJ; Leslie KK; Gonzalez-Bosquet J
Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30866519
[TBL] [Abstract] [Full Text] [Related]
12. PRAME promotes epithelial-to-mesenchymal transition in triple negative breast cancer.
Al-Khadairi G; Naik A; Thomas R; Al-Sulaiti B; Rizly S; Decock J
J Transl Med; 2019 Jan; 17(1):9. PubMed ID: 30602372
[TBL] [Abstract] [Full Text] [Related]
13. Identification of somatic genetic alterations in ovarian clear cell carcinoma with next generation sequencing.
Shibuya Y; Tokunaga H; Saito S; Shimokawa K; Katsuoka F; Bin L; Kojima K; Nagasaki M; Yamamoto M; Yaegashi N; Yasuda J
Genes Chromosomes Cancer; 2018 Feb; 57(2):51-60. PubMed ID: 29044863
[TBL] [Abstract] [Full Text] [Related]
14. Nintedanib in ovarian cancer.
Khalique S; Banerjee S
Expert Opin Investig Drugs; 2017 Sep; 26(9):1073-1081. PubMed ID: 28721753
[TBL] [Abstract] [Full Text] [Related]
15. E2F2 induces MCM4, CCNE2 and WHSC1 upregulation in ovarian cancer and predicts poor overall survival.
Xie L; Li T; Yang LH
Eur Rev Med Pharmacol Sci; 2017 May; 21(9):2150-2156. PubMed ID: 28537669
[TBL] [Abstract] [Full Text] [Related]
16. PDGF-AA mediates mesenchymal stromal cell chemotaxis to the head and neck squamous cell carcinoma tumor microenvironment.
Watts TL; Cui R; Szaniszlo P; Resto VA; Powell DW; Pinchuk IV
J Transl Med; 2016 Dec; 14(1):337. PubMed ID: 27931212
[TBL] [Abstract] [Full Text] [Related]
17. Perivascular pdgfr-β is an independent marker for prognosis in renal cell carcinoma.
Frödin M; Mezheyeuski A; Corvigno S; Harmenberg U; Sandström P; Egevad L; Johansson M; Östman A
Br J Cancer; 2017 Jan; 116(2):195-201. PubMed ID: 27931046
[TBL] [Abstract] [Full Text] [Related]
18. Platelet-Derived Growth Factor in the ovarian Follicle Attracts the Stromal Cells of the Fallopian Tube Fimbriae.
Yeh CH; Chen PC; Chen CH; Hsu CF; Huang RL; Ding DC; Chu TY
PLoS One; 2016; 11(7):e0158266. PubMed ID: 27379403
[TBL] [Abstract] [Full Text] [Related]
19. Fertility-preservation counselling and treatment for medical reasons: data from a multinational network of over 5000 women.
von Wolff M; Dittrich R; Liebenthron J; Nawroth F; Schüring AN; Bruckner T; Germeyer A
Reprod Biomed Online; 2015 Nov; 31(5):605-12. PubMed ID: 26380870
[TBL] [Abstract] [Full Text] [Related]
20. A pilot study of JI-101, an inhibitor of VEGFR-2, pdgfr-β, and EphB4 receptors, in combination with everolimus and as a single agent in an ovarian cancer expansion cohort.
Werner TL; Wade ML; Agarwal N; Boucher K; Patel J; Luebke A; Sharma S
Invest New Drugs; 2015 Dec; 33(6):1217-24. PubMed ID: 26365907
[TBL] [Abstract] [Full Text] [Related]
[Next]
